233. ウォルフラム症候群 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 12 / 薬物数 : 14 - (DrugBank : 6) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 6

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Acetylcysteine
   Hadassah Medical Organization
      2016   Phase 2/Phase 3   NCT02882477   Israel
AMX0035
   Amylyx Pharmaceuticals Inc.
      2023   Phase 2   NCT05676034   United States
Dantrolene sodium
   Washington University School of Medicine
      2017   Phase 1/Phase 2   NCT02829268   United States
Deferiprone
   Hadassah Medical Organization
      2016   Phase 2/Phase 3   NCT02882477   Israel
Depakine
   Centre d'Etude des Cellules Souches
      2021   Phase 2   NCT04940572   France;Spain
Depakine chrono 500 MG
   CECS/I-Stem
      2021   Phase 2   EUCTR2020-004594-43-FR   France;Spain
Depakine chrono® 500 MG
   CECS/I-Stem
      2021   Phase 2   EUCTR2020-004594-43-FR   France;Spain
Exenatide
   Hadassah Medical Organization
      2011   -   NCT01302327   -
Mounjaro - tirzepatide
   OSPEDALE SAN RAFFAELE
      2023   Phase 2   EUCTR2022-003853-70-IT   Italy
Sitagliptin and metformin
   Hadassah Medical Organization
      2016   Phase 2/Phase 3   NCT02882477   Israel
Sodium valproate 200 MG gastro-resistant tablets
   University of Birmingham
      2020   Phase 2   EUCTR2017-001215-37-PL   France;Poland;United Kingdom
Sodium valproate 200MG E/C tablet
   University of Birmingham
      2018   Phase 2   NCT03717909   France;Poland;Spain;United Kingdom
Sodium valproate wockhardt 200MG gastro-resistant tablets
   University of Birmingham
      2020   Phase 2   EUCTR2017-001215-37-FR   France;Poland;Spain;United Kingdom
      2018   Phase 2   EUCTR2017-001215-37-GB   France;Poland;Spain;United Kingdom
Tirzepatide
   Ospedale San Raffaele
      2024   Phase 2   NCT05659368   Italy